FDA Extends Mirena IUD for Eight Years of Use
Mirena, a long-acting hormonal IUD, was previously approved to prevent pregnancy for up to seven years.
The FDA has approved a supplemental new drug application (sNDA) that extends the duration of use of Bayer’s intrauterine device (IUD) Mirena (levonorgestrel-releasing intrauterine system) by one more year, making it available to prevent pregnancy for up to eight years.
Yesmean Wahdan
“Now more than ever, it’s important to help ensure that women have the options they need when it comes to contraception needs at various stages of their reproductive life,” stated Yesmean Wahdan, vice president, U.S. medical affairs, Bayer Women’s Healthcare, said in a press release.
Mirena, a long-acting hormonal IUD, was previously approved to prevent pregnancy for up to seven years by releasing small amounts of progestin hormone called levonorgestrel into the uterus. It also is the only FDA-approved IUD to treat heavy periods for up to 5 years in women who choose intrauterine contraception and can be used in women if they have previously given birth or not.
The approval is based on results from a phase 3 extension trial evaluating the efficacy and safety of Mirena. This trial enrolled in 362 women and demonstrated contraceptive efficacy greater than 99% during years six to year of use.
FDA Approves Two More Denosumab Biosimilars, Conexxence and Bomyntra
March 27th 2025The fourth pair of denosumab biosimilars, Conexxence and Bomyntra, are expected to launch in the United States in mid 2025, as a result of a global settlement with Amgen, according to a company news release.
Read More
In this episode of the "Meet the Board" podcast series, Briana Contreras, Managed Healthcare Executive editor, speaks with Ateev Mehrotra, a member of the MHE editorial advisory board and a professor of healthcare policy and medicine at Harvard Medical School. Mehtrotra is also a hospitalist at the Beth Israel Deaconess Medical Center in Boston. In the discussion, Contreras gets to know Mehrotra more on a personal level and picks his brain on some of his research interests including telehealth, alternative payment models and price transparency.
Listen
FDA Approves Amvuttra for ATTR-CM in Extended Label
March 21st 2025This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with cardiomyopathy (ATTR-CM) and the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR-PN) in adults.
Read More
